BridgeBio Pharma (NASDAQ:BBIO) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $70.00 price target on the stock. Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on […]

Related Keywords

United States ,Arizona ,American ,Bridgebio Pharma ,Raymond James ,Bio Pharma ,Kokusai Asset Management Co ,Cantor Fitzgerald ,Bridgebio Pharma Inc ,Mitsubishi Ufj ,Jpmorgan Chase Co ,American International Group Inc ,Nasdaq ,Free Report ,Moderate Buy ,Get Free Report ,State Retirement System ,International Group ,Asset Management ,Bridgebio Pharma Daily ,